# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Benjamin Franklin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN004-SYN-TD
- Date: 1782-03-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lydia Penhallow, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Reason for visit

Primary care visit for recurrent gout flares and painful, interrupted urination with blood in the urine. **S**

## Historical basis

- Benjamin Franklin was born in Boston on January 17, 1706 (New Style); an editor's note to his autobiography gives the date as Sunday, January 6, old style, 1706, in a house on Milk Street. **D**
- In a letter of July 31, 1786, Franklin recalled that in 1724, as a compositor at Palmer's printing house in London, he sometimes heated his case of type before the fire to warm his hands, until an old workman warned him he might lose the use of his hands, and that he had felt a kind of obscure pain in the bones of his hand when working over very hot type. **D**
- A 2008 review of his medical history by Finger and Hagemann concluded that he suffered repeated attacks of gout and a large bladder stone, which caused considerable pain and markedly decreased his mobility. **D**
- The same review argues that several factors that raise uric acid converged in him, including sex, genetics, diet, drinking, advanced age, psoriasis, and possible lead poisoning from lead exposure. **R**
- Franklin wrote the Dialogue between Franklin and the Gout, headed Midnight, October 22, 1780, in which the Gout tells him he has eaten and drunk too freely and indulged his indolence; a 2023 rheumatology review states that he woke with a gout attack that night. **D**
- In a letter from Passy dated March 12, 1781, to Samuel Huntington, President of Congress, Franklin wrote that he had passed his seventy-fifth year and that the long and severe fit of the gout he had the last winter had shaken him exceedingly, leaving him far from his former bodily strength. **D**
- The 1806 edition of his works states that he had been little subject to disease, except an attack of the gout occasionally, until about the year 1781, when he was first attacked with symptoms of the calculous complaint, which continued during his life. **D**
- In his autobiography Franklin wrote that at the beginning of February 1726/7 he was taken ill with a pleurisy that very nearly carried him off. **D**
- The 1806 edition of his works adds that in 1735 he had a severe pleurisy that ended in an abscess of the left lobe of his lungs, and that a second similar attack some years later left no lasting effect on his breathing. **D**
- His autobiography records that he never knew his father or mother to have any sickness but that of which they died, his father Josiah at 89 in 1744 and his mother Abiah at 85 in 1752. **D**
- Franklin wrote that in 1736 he lost a son, a boy of four, to smallpox taken in the common way, and regretted that he had not had him inoculated. **D**
- A 2023 review describes him as overweight and as probably having had consequences of the metabolic syndrome, including gout. **R**

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- Painful, interrupted urination and blood in the urine after car journeys. **S**
- Gout flares keep confining him to his chair, and he does not want to give up wine and good dinners entirely. **S**

## Strengths and supports

- Supports: family nearby, a wide circle of friends and correspondents, and a regular chess partner **S**

## Medications and allergies

- Hydrochlorothiazide 25 mg oral tablet, one tablet by mouth daily **S**
- Losartan 50 mg oral tablet, one tablet by mouth daily **S**
- Allopurinol 100 mg oral tablet, one tablet by mouth daily **S**
- Colchicine 0.6 mg oral tablet, one tablet by mouth daily for flare prophylaxis **S**
- Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain, no more than 3 g a day **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- 1724: Occupational exposure to heated type metal as a compositor in London, with an obscure pain in the bones of the hand; he stopped heating the type **D** (CLM-0002)
- February 1727 (1726/7 Old Style): Pleurisy that very nearly carried him off **D** (CLM-0010)
- 1735: Severe pleurisy ending in an abscess of the left lung, with full recovery **D** (CLM-0011)
- October 22, 1780: Gout attack at midnight, recorded in his Dialogue between Franklin and the Gout **D** (CLM-0005)
- Winter of 1780 to 1781: Long and severe fit of gout through the winter, leaving him weakened **D** (CLM-0006)
- About 1781: First symptoms of the calculous complaint (bladder stone) **D** (CLM-0007)

## Procedures and immunizations

- 1782-03-02 to 1782-03-02: Non-contrast low-dose CT of the abdomen and pelvis: single 2.6 cm bladder stone of about 420 Hounsfield units, suggesting uric acid; no kidney or ureteric stones; no hydronephrosis; enlarged prostate **S**
- 1782-03-02 to 1782-03-02: 12-lead electrocardiogram: sinus rhythm, no left ventricular hypertrophy **S**
- 1781-10-08: High-dose influenza vaccine, 1781-1782 season **S**
- 1779-11-06: Pneumococcal conjugate vaccine PCV20 **S**
- 1778-04-11: Recombinant zoster vaccine, two-dose series completed **S**
- 1774-09-17: Tdap vaccine **S**

## Family history

- father: Died in 1744 at 89; no illness before his last; cause not recorded in the cited source **D** (CLM-0012)
- mother: Died in 1752 at 85; no illness before her last; cause not recorded in the cited source **D** (CLM-0012)
- natural son: Died in 1736 at four of smallpox **D** (CLM-0013)

## Measurements

Serum urate: 9.1 mg/dL (high); Sodium: 140 mmol/L; Potassium: 4.1 mmol/L; Bicarbonate (total CO2): 25 mmol/L; BUN: 22 mg/dL; Creatinine: 1.36 mg/dL (high); eGFR: 54 mL/min/1.73 m² (low); Glucose: 98 mg/dL; Calcium: 9.5 mg/dL; Phosphate: 3.4 mg/dL; Intact PTH: 52 pg/mL; 25-hydroxyvitamin D: 34 ng/mL; Hemoglobin: 14.2 g/dL; ALT: 24 U/L; LDL cholesterol: 128 mg/dL (high); HbA1c: 5.6%; Urine albumin-creatinine ratio: 18 mg/g; Urine pH: 5.2 [pH]; Urine red cells: 12 /[HPF] (high); Blood lead: 3.1 ug/dL; IPSS: 16; KFRE 2-year kidney failure risk: 0.2%; KFRE 5-year kidney failure risk: 0.6%. All results are synthetic.

BP 148/86 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 96 kg; BMI 31.3 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, witty, and curious; asks for the evidence behind each recommendation; Mood cheerful; cognition intact. Functional status: At intake, flares stop him walking for a week at a time, and jolting car rides and long walks bring on bladder pain; Walking 30 minutes most days and travelling without urinary pain by the six-month review. Physical examination is intentionally limited. **S**

## Assessment

1. Gout with recurrent flares, mostly in the right big toe, without tophi; synthetic modern diagnosis linked to his documented gout; status draft. **S**
2. Chronic kidney disease stage G3a A1; status draft. **S**
3. Essential hypertension; status draft. **S**

## Plan

- Start allopurinol 100 mg daily and raise it by 100 mg every 2 to 5 weeks until serum urate is below 6 mg/dL; HLA-B*58:01 testing is not indicated, because he is not of Southeast Asian or African ancestry. Guideline: 2020 American College of Rheumatology Guideline for the Management of Gout (2020) **S**
- Colchicine 0.6 mg daily for three to six months as flare prophylaxis; treat flares with a short prednisone course or extra colchicine, and avoid NSAIDs because of chronic kidney disease. Guideline: 2020 American College of Rheumatology Guideline for the Management of Gout (2020); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, and benign prostatic hyperplasia monographs (2026) **S**
- Replace hydrochlorothiazide with losartan, which lowers blood pressure and slightly lowers urate; check potassium and creatinine 2 to 4 weeks after starting. Guideline: 2020 American College of Rheumatology Guideline for the Management of Gout (2020); 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, and benign prostatic hyperplasia monographs (2026) **S**
- Urology referral to confirm and remove the bladder stone, look for bladder outlet obstruction and other causes of hematuria, and advise on stone prevention. Guideline: Medical Management of Kidney Stones: AUA Guideline (2014, amended 2019); EAU Guidelines on Urolithiasis (including bladder stones) (2025); Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2023 amendment) **S**
- CMID kidney and blood pressure monitoring: blood pressure every visit; eGFR and urine albumin yearly at G3a A1; calcium, phosphate, and PTH at baseline; hemoglobin and the kidney failure risk equation yearly; statin for age over 50 with eGFR below 60; medication review for NSAIDs every visit. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, and benign prostatic hyperplasia monographs (2026) **S**
- Limit alcohol, especially beer and spirits, and purine-rich meat, organ meat, and shellfish; avoid sugar-sweetened drinks; aim for gradual weight loss and daily walking. Guideline: 2020 American College of Rheumatology Guideline for the Management of Gout (2020) **S**

## Guideline basis

- 2020 American College of Rheumatology Guideline for the Management of Gout (2020), American College of Rheumatology (Arthritis Care Res 2020;72(6):744-760)
- Medical Management of Kidney Stones: AUA Guideline (2014, amended 2019), American Urological Association
- EAU Guidelines on Urolithiasis (including bladder stones) (2025), European Association of Urology
- Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2023 amendment), American Urological Association
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney Int 2024;105(4S):S117-S314)
- 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017), American College of Cardiology and American Heart Association (Hypertension 2018;71(6):e13-e115)
- CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, and benign prostatic hyperplasia monographs (2026), Aether Forge
